Gastric Cancer Therapeutics Market Research Report To Design A Cohesive And Predictive Business Strategy

Gastric Cancer Therapeutics Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Gastric Cancer Therapeutics Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.

To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/194

Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.

Major Players In This Market Are: Pfizer, Eli Lilly, GlaxoSmithKline plc, Kuhnil Pharmaceutical/Daiichi Sankyo, BMS, Merck KGaA, AstraZeneca, Otsuka Holdings Co. Ltd., Sanofi, and F. Hoffmann-La Roche Ltd.

Gastric cancer develops within the inside layer of the stomach and is characterized by upper abdominal pain, heartburn, sudden weight loss, yellowing of the skin, blood in the stool, loss of appetite, and nausea. It can spread to other body parts such as lungs, liver, the lining of the abdomen, lymph nodes, and bones. Majority of gastric cancers are gastric carcinomas. Helicobacter pylori – a type of bacteria— is a major cause of gastric cancer, accounting for around 60% of the cases. The severity of the disease varies with the type of H. pylori. Other factors such as smoking and eating pickled vegetables are also responsible for gastric cancer. Around 1 in 10 cases of the disease are inherited and 1% to 3% of the cases are due to hereditary syndromes such as hereditary gastric cancer.

According to World Cancer Research Fund International, 952,000 new cases of gastric cancer were diagnosed in 2012 and the disease was the fifth-most common type of cancer in the world. Therefore, various institutes, universities, and government bodies are focused on R&D of effective therapies for gastric cancer.

Gastric Cancer Therapeutics Market Taxonomy

On the basis of type of treatment, the global gastric cancer therapeutics market is segmented into:

• • Surgery

  • Targeted drugs therapy

  • Chemotherapy

  • Radiation therapy

  • Others

On the basis of end user, the global gastric cancer therapeutics market is segmented into:

• • Hospitals

  • Clinics

  • Specialized cancer treatment centers

  • Ambulatory surgical centers

  • Others

On the basis of region, the global gastric cancer therapeutics market is segmented into:

• • North America

  • Latin America

  • Europe

  • Asia Pacific

  • Middle East

  • Africa

Global Gastric Cancer Therapeutics Market: Drivers

High incidence of gastric cancer in Asia Pacific to boost growth of the overall global gastric cancer therapeutics market over the forecast period. The stage or phase of the disease during diagnosis determines the survival rate in gastric cancer. In Asia Pacific, majority of the geriatric population suffers from gastric cancer and most of the cases are detected at the later stage of the disease. Therefore, growing geriatric population in the region is also boosting growth of the market. Moreover, increasing health awareness may lead to early detection of the disease, thereby boosting growth of the global gastric cancer therapeutics market over the forecast period.

Currently, angiogenesis inhibitors, new chemotherapies, and HER2-targeted therapy are some of the treatment option for gastric cancer. However, demand for therapeutics for the treatment of HER2-negative stomach cancer is high and the demand for targeted therapies is increasing. Such scenario is expected to boost growth of the global gastric cancer therapeutics market.

Global Gastric Cancer Therapeutics Market: Regional Analysis

North America is expected to hold dominant position in the global gastric cancer therapeutics market over the forecast period. This is attributed to high prevalence of gastric cancer in the U.S. For instance, according to National Cancer Institute, an estimated 79,843 people suffered from gastric cancer in the U.S. in 2013. According to the same source, gastric cancer represented 1.6% of the new cancer cases reported in the U.S. and 26,370 new cases of the disease were reported that led to 10,730 deaths in 2016.

Major players operating in the global gastric cancer therapeutics market are focused on launching new products to expand their product portfolio. For instance, in April 2019, F. Hoffmann-La Roche AG launched VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer.

Major market players are focused on adopting collaboration strategies to develop novel therapies for gastric cancer. For instance, in February 2019, GlaxoSmithKline plc. and Merck KGaA entered into a global strategic alliance to jointly develop and commercialize M7824, an investigational bifunctional fusion protein immunotherapy under clinical development stage, for the treatment of human papillomavirus-associated cancers, biliary tract cancer (BTC), and gastric cancer.

Key market players are also focused on gaining regulatory approvals to expand their product portfolio. Fro instance, in August 2019, Taiho Pharmaceutical Co., Ltd. obtained additional indication of unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy for its anticancer agent LONSURF, an oral anticancer drug that uses the combination of trifluridine (antineoplastic nucleoside analogue) and tipiracil (a thymidine phosphorylase inhibitor), from the Japanese Ministry of Health, Labor and Welfare.

Buy This Premium Report Of Gastric Cancer Therapeutics Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/194

In this study, the years considered to estimate the market size of Gastric Cancer Therapeutics are as follows:

History Year: 2017-2020

Base Year: 2020

Estimated Year: 2021

Forecast Year 2021 to 2028

The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Gastric Cancer Therapeutics Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Gastric Cancer Therapeutics Market are also given.

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Gastric Cancer Therapeutics Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Gastric Cancer Therapeutics Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.

To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/194

Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.

Major Players In This Market Are: Pfizer, Eli Lilly, GlaxoSmithKline plc, Kuhnil Pharmaceutical/Daiichi Sankyo, BMS, Merck KGaA, AstraZeneca, Otsuka Holdings Co. Ltd., Sanofi, and F. Hoffmann-La Roche Ltd.

Gastric cancer develops within the inside layer of the stomach and is characterized by upper abdominal pain, heartburn, sudden weight loss, yellowing of the skin, blood in the stool, loss of appetite, and nausea. It can spread to other body parts such as lungs, liver, the lining of the abdomen, lymph nodes, and bones. Majority of gastric cancers are gastric carcinomas. Helicobacter pylori – a type of bacteria— is a major cause of gastric cancer, accounting for around 60% of the cases. The severity of the disease varies with the type of H. pylori. Other factors such as smoking and eating pickled vegetables are also responsible for gastric cancer. Around 1 in 10 cases of the disease are inherited and 1% to 3% of the cases are due to hereditary syndromes such as hereditary gastric cancer.

According to World Cancer Research Fund International, 952,000 new cases of gastric cancer were diagnosed in 2012 and the disease was the fifth-most common type of cancer in the world. Therefore, various institutes, universities, and government bodies are focused on R&D of effective therapies for gastric cancer.

Gastric Cancer Therapeutics Market Taxonomy

On the basis of type of treatment, the global gastric cancer therapeutics market is segmented into:

• • Surgery

  • Targeted drugs therapy

  • Chemotherapy

  • Radiation therapy

  • Others

On the basis of end user, the global gastric cancer therapeutics market is segmented into:

• • Hospitals

  • Clinics

  • Specialized cancer treatment centers

  • Ambulatory surgical centers

  • Others

On the basis of region, the global gastric cancer therapeutics market is segmented into:

• • North America

  • Latin America

  • Europe

  • Asia Pacific

  • Middle East

  • Africa

Global Gastric Cancer Therapeutics Market: Drivers

High incidence of gastric cancer in Asia Pacific to boost growth of the overall global gastric cancer therapeutics market over the forecast period. The stage or phase of the disease during diagnosis determines the survival rate in gastric cancer. In Asia Pacific, majority of the geriatric population suffers from gastric cancer and most of the cases are detected at the later stage of the disease. Therefore, growing geriatric population in the region is also boosting growth of the market. Moreover, increasing health awareness may lead to early detection of the disease, thereby boosting growth of the global gastric cancer therapeutics market over the forecast period.

Currently, angiogenesis inhibitors, new chemotherapies, and HER2-targeted therapy are some of the treatment option for gastric cancer. However, demand for therapeutics for the treatment of HER2-negative stomach cancer is high and the demand for targeted therapies is increasing. Such scenario is expected to boost growth of the global gastric cancer therapeutics market.

Global Gastric Cancer Therapeutics Market: Regional Analysis

North America is expected to hold dominant position in the global gastric cancer therapeutics market over the forecast period. This is attributed to high prevalence of gastric cancer in the U.S. For instance, according to National Cancer Institute, an estimated 79,843 people suffered from gastric cancer in the U.S. in 2013. According to the same source, gastric cancer represented 1.6% of the new cancer cases reported in the U.S. and 26,370 new cases of the disease were reported that led to 10,730 deaths in 2016.

Major players operating in the global gastric cancer therapeutics market are focused on launching new products to expand their product portfolio. For instance, in April 2019, F. Hoffmann-La Roche AG launched VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer.

Major market players are focused on adopting collaboration strategies to develop novel therapies for gastric cancer. For instance, in February 2019, GlaxoSmithKline plc. and Merck KGaA entered into a global strategic alliance to jointly develop and commercialize M7824, an investigational bifunctional fusion protein immunotherapy under clinical development stage, for the treatment of human papillomavirus-associated cancers, biliary tract cancer (BTC), and gastric cancer.

Key market players are also focused on gaining regulatory approvals to expand their product portfolio. Fro instance, in August 2019, Taiho Pharmaceutical Co., Ltd. obtained additional indication of unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy for its anticancer agent LONSURF, an oral anticancer drug that uses the combination of trifluridine (antineoplastic nucleoside analogue) and tipiracil (a thymidine phosphorylase inhibitor), from the Japanese Ministry of Health, Labor and Welfare.

Buy This Premium Report Of Gastric Cancer Therapeutics Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/194

In this study, the years considered to estimate the market size of Gastric Cancer Therapeutics are as follows:

History Year: 2017-2020

Base Year: 2020

Estimated Year: 2021

Forecast Year 2021 to 2028

The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Gastric Cancer Therapeutics Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Gastric Cancer Therapeutics Market are also given.

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837